UBS analyst Karl Keirstead raised the firm’s price target on Veeva to $215 from $185 and keeps a Neutral rating on the shares after receiving feedback from three large pharma customers of the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV: